一页纸薄的个人主页 - 老虎社区

一页纸薄

一页纸薄

暂无个人介绍

IP属地：贵州

52关注

0粉丝

0主题

0勋章

05-17

$XPEV 20240607 8.0 CALL$ 小鹏下周发布会加一季报能不能发力站上九块钱

05-10

新冠疫苗还有人买？

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3521146191223080","uuid":"3521146191223080","gmtCreate":1558052169614,"gmtModify":1558052169614,"name":"一页纸薄","pinyin":"yyzbyiyezhibo","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/7a2adb6aea52a7d163b3deac56fb41f1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":52,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"45aa8c9032204ad8bee19bb27da4edb8-1","templateUuid":"45aa8c9032204ad8bee19bb27da4edb8","name":"交易笔数","description":"累计达100笔","bigImgUrl":"https://static.tigerbbs.com/f6040a65e0c6e125e4dcfe0101de45ee","smallImgUrl":"https://static.tigerbbs.com/f803dba33fef1aa87b64be09f4f064ee","grayImgUrl":"https://static.tigerbbs.com/5dfa45d4a1e98a2d8c2e1b4253ddd916","redirectLinkEnabled":0,"redirectLink":"https://www.itigerup.com/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5100},{"badgeId":"5697d37f217342faaa027fdb5a6e7c12-2","templateUuid":"5697d37f217342faaa027fdb5a6e7c12","name":"单笔平均盈利排行","description":"Top 30%","bigImgUrl":"https://static.tigerbbs.com/7554ebe7d1898f430d98e76f650368cf","smallImgUrl":"https://static.tigerbbs.com/fe4bec6a19cf99388987516558515819","grayImgUrl":"https://static.tigerbbs.com/18dd3e6a5c1a81de02d26eef5a5c7f28","redirectLinkEnabled":0,"redirectLink":"https://www.itigerup.com/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5200},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"94.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":7,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":1,"location":"贵州","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":13,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":306765702254680,"gmtCreate":1715928646646,"gmtModify":1715928752568,"author":{"id":"3521146191223080","authorId":"3521146191223080","name":"一页纸薄","avatar":"https://static.tigerbbs.com/7a2adb6aea52a7d163b3deac56fb41f1","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3521146191223080","authorIdStr":"3521146191223080"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/OPT/XPEV 20240607 8.0 CALL\">$XPEV 20240607 8.0 CALL$ </a> 小鹏下周发布会加一季报能不能发力站上九块钱","listText":"<a href=\"https://laohu8.com/OPT/XPEV 20240607 8.0 CALL\">$XPEV 20240607 8.0 CALL$ </a> 小鹏下周发布会加一季报能不能发力站上九块钱","text":"$XPEV 20240607 8.0 CALL$ 小鹏下周发布会加一季报能不能发力站上九块钱","images":[{"img":"https://static.tigerbbs.com/1678488d8e1fc4f9eb561d124d673d0b","width":"1022","height":"1608"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306765702254680","isVote":1,"tweetType":1,"viewCount":679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":304354211373216,"gmtCreate":1715339739657,"gmtModify":1715345482194,"author":{"id":"3521146191223080","authorId":"3521146191223080","name":"一页纸薄","avatar":"https://static.tigerbbs.com/7a2adb6aea52a7d163b3deac56fb41f1","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3521146191223080","authorIdStr":"3521146191223080"},"themes":[],"htmlText":"新冠疫苗还有人买？","listText":"新冠疫苗还有人买？","text":"新冠疫苗还有人买？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/304354211373216","repostId":"2434188644","repostType":4,"isVote":1,"tweetType":1,"viewCount":367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":306765702254680,"gmtCreate":1715928646646,"gmtModify":1715928752568,"author":{"id":"3521146191223080","authorId":"3521146191223080","name":"一页纸薄","avatar":"https://static.tigerbbs.com/7a2adb6aea52a7d163b3deac56fb41f1","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3521146191223080","authorIdStr":"3521146191223080"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/OPT/XPEV 20240607 8.0 CALL\">$XPEV 20240607 8.0 CALL$ </a> 小鹏下周发布会加一季报能不能发力站上九块钱","listText":"<a href=\"https://laohu8.com/OPT/XPEV 20240607 8.0 CALL\">$XPEV 20240607 8.0 CALL$ </a> 小鹏下周发布会加一季报能不能发力站上九块钱","text":"$XPEV 20240607 8.0 CALL$ 小鹏下周发布会加一季报能不能发力站上九块钱","images":[{"img":"https://static.tigerbbs.com/1678488d8e1fc4f9eb561d124d673d0b","width":"1022","height":"1608"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306765702254680","isVote":1,"tweetType":1,"viewCount":679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":304354211373216,"gmtCreate":1715339739657,"gmtModify":1715345482194,"author":{"id":"3521146191223080","authorId":"3521146191223080","name":"一页纸薄","avatar":"https://static.tigerbbs.com/7a2adb6aea52a7d163b3deac56fb41f1","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3521146191223080","authorIdStr":"3521146191223080"},"themes":[],"htmlText":"新冠疫苗还有人买？","listText":"新冠疫苗还有人买？","text":"新冠疫苗还有人买？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/304354211373216","repostId":"2434188644","repostType":4,"repost":{"id":"2434188644","kind":"news","pubTimestamp":1715325808,"share":"https://www.laohu8.com/m/news/2434188644?lang=&edition=full","pubTime":"2024-05-10 15:23","market":"us","language":"zh","title":"诺瓦瓦克斯医药与赛诺菲就新冠疫苗达成数十亿美元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2434188644","media":"智通财经","summary":"5月10日，$诺瓦瓦克斯医药$周五宣布，与法国制药巨头$赛诺菲$达成了一项价值数十亿美元的合作协议。此外，诺瓦瓦克斯医药还将从赛诺菲销售的新冠疫苗以及针对冠状病毒和流感的组合疫苗中获得特许权使用费。根据协议条款，诺瓦瓦克斯医药将在今年剩余时间内主导其新冠疫苗的商业化，并计划于2025年将大部分责任移交给赛诺菲。","content":"<html><head></head><body><p>5月10日，<strong><a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯医药</a>盘前暴涨到停不下来，截至发稿涨幅超200%！</strong>诺瓦瓦克斯医药周五宣布，与法国制药巨头<a href=\"https://laohu8.com/S/SNY\">赛诺菲</a>达成了一项价值数十亿美元的合作协议。根据协议，双方将从明年开始联合商业化诺瓦瓦克斯医药的新冠疫苗，并共同开发针对冠状病毒和流感的组合疫苗。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bcbbd094d7336d45ddf2c7feeb823779\" title=\"\" tg-width=\"450\" tg-height=\"126\"/></p><p>诺瓦瓦克斯医药首席执行官约翰·雅各布斯(John Jacobs)表示，这项许可协议将有助于公司解除此前发布的“持续经营”警告，该警告是由于市场对其持续运营能力存疑而于2023年2月首次发布的。</p><p>对于这家一直在努力的疫苗制造商来说，此次合作标志着一个重要的转折点，其基于蛋白质的新冠疫苗被卫生官员视为对那些不愿接种信使RNA疫苗人群的宝贵替代选择。</p><p>在该合作协议中，赛诺菲将利用诺瓦瓦克斯医药的新冠疫苗和旗舰疫苗技术Matrix-M佐剂来开发新的疫苗产品。作为交易的一部分，赛诺菲将向诺瓦瓦克斯医药支付5亿美元的预付款，并在达成开发、监管和上市里程碑时支付高达7亿美元的额外款项。这笔交易的总价值大约是诺瓦瓦克斯医药目前市值的两倍。</p><p>此外，诺瓦瓦克斯医药还将从赛诺菲销售的新冠疫苗以及针对冠状病毒和流感的组合疫苗中获得特许权使用费。对于赛诺菲使用Matrix-M佐剂开发的每种产品，诺瓦瓦克斯医药还有权获得高达2亿美元的额外启动和销售里程碑付款以及特许权使用费。赛诺菲还将持有诺瓦瓦克斯医药不到5%的股份。</p><p>雅各布斯表示，这项交易将为诺瓦瓦克斯医药带来充足的资本，使其能够持续经营，并有机会将战略更多地转向其最擅长的领域，为所有利益相关者，包括股东，创造更多价值。</p><p>此外，该交易还将支持公司实现其疫苗技术平台改善全球公共卫生的使命，这是单凭公司自身资源难以实现的。</p><p>根据协议条款，诺瓦瓦克斯医药将在今年剩余时间内主导其新冠疫苗的商业化，并计划于2025年将大部分责任移交给赛诺菲。赛诺菲不会参与监督与诺瓦瓦克斯医药现有合作协议的国家的商业化，这些国家包括印度、日本和韩国，以及与该公司签订了新冠疫苗购买协议的国家。</p><p>雅各布斯认为，赛诺菲作为一家大型制药公司，其参与将增加诺瓦瓦克斯医药新冠疫苗的市场份额和可见度，从而扩大患者获取疫苗的机会。此外，赛诺菲还将负责开发和商业化任何包含其流感疫苗和诺瓦瓦克斯医药新冠疫苗的组合产品。</p><p>雅各布斯强调：“通过与赛诺菲这样的全球领先企业合作，我们相信这将大大增加我们更快推出多种新疫苗的机会。”</p><p>除了合作协议，诺瓦瓦克斯医药还计划在今年晚些时候启动针对新冠病毒和流感的联合疫苗以及独立流感疫苗的后期试验。</p><p>此前，公司曾表示试验将仅包括联合疫苗。雅各布斯表示，如果试验成功，公司将不仅拥有一种潜在的可许可疫苗，而且还将开辟自身的有机产品线。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺瓦瓦克斯医药与赛诺菲就新冠疫苗达成数十亿美元合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺瓦瓦克斯医药与赛诺菲就新冠疫苗达成数十亿美元合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-10 15:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1119740.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月10日，诺瓦瓦克斯医药盘前暴涨到停不下来，截至发稿涨幅超200%！诺瓦瓦克斯医药周五宣布，与法国制药巨头赛诺菲达成了一项价值数十亿美元的合作协议。根据协议，双方将从明年开始联合商业化诺瓦瓦克斯医药的新冠疫苗，并共同开发针对冠状病毒和流感的组合疫苗。诺瓦瓦克斯医药首席执行官约翰·雅各布斯(John Jacobs)表示，这项许可协议将有助于公司解除此前发布的“持续经营”警告，该警告是由于市场对其...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1119740.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"SNY":"赛诺菲安万特","NVAX":"诺瓦瓦克斯医药"},"source_url":"http://www.zhitongcaijing.com/content/detail/1119740.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2434188644","content_text":"5月10日，诺瓦瓦克斯医药盘前暴涨到停不下来，截至发稿涨幅超200%！诺瓦瓦克斯医药周五宣布，与法国制药巨头赛诺菲达成了一项价值数十亿美元的合作协议。根据协议，双方将从明年开始联合商业化诺瓦瓦克斯医药的新冠疫苗，并共同开发针对冠状病毒和流感的组合疫苗。诺瓦瓦克斯医药首席执行官约翰·雅各布斯(John Jacobs)表示，这项许可协议将有助于公司解除此前发布的“持续经营”警告，该警告是由于市场对其持续运营能力存疑而于2023年2月首次发布的。对于这家一直在努力的疫苗制造商来说，此次合作标志着一个重要的转折点，其基于蛋白质的新冠疫苗被卫生官员视为对那些不愿接种信使RNA疫苗人群的宝贵替代选择。在该合作协议中，赛诺菲将利用诺瓦瓦克斯医药的新冠疫苗和旗舰疫苗技术Matrix-M佐剂来开发新的疫苗产品。作为交易的一部分，赛诺菲将向诺瓦瓦克斯医药支付5亿美元的预付款，并在达成开发、监管和上市里程碑时支付高达7亿美元的额外款项。这笔交易的总价值大约是诺瓦瓦克斯医药目前市值的两倍。此外，诺瓦瓦克斯医药还将从赛诺菲销售的新冠疫苗以及针对冠状病毒和流感的组合疫苗中获得特许权使用费。对于赛诺菲使用Matrix-M佐剂开发的每种产品，诺瓦瓦克斯医药还有权获得高达2亿美元的额外启动和销售里程碑付款以及特许权使用费。赛诺菲还将持有诺瓦瓦克斯医药不到5%的股份。雅各布斯表示，这项交易将为诺瓦瓦克斯医药带来充足的资本，使其能够持续经营，并有机会将战略更多地转向其最擅长的领域，为所有利益相关者，包括股东，创造更多价值。此外，该交易还将支持公司实现其疫苗技术平台改善全球公共卫生的使命，这是单凭公司自身资源难以实现的。根据协议条款，诺瓦瓦克斯医药将在今年剩余时间内主导其新冠疫苗的商业化，并计划于2025年将大部分责任移交给赛诺菲。赛诺菲不会参与监督与诺瓦瓦克斯医药现有合作协议的国家的商业化，这些国家包括印度、日本和韩国，以及与该公司签订了新冠疫苗购买协议的国家。雅各布斯认为，赛诺菲作为一家大型制药公司，其参与将增加诺瓦瓦克斯医药新冠疫苗的市场份额和可见度，从而扩大患者获取疫苗的机会。此外，赛诺菲还将负责开发和商业化任何包含其流感疫苗和诺瓦瓦克斯医药新冠疫苗的组合产品。雅各布斯强调：“通过与赛诺菲这样的全球领先企业合作，我们相信这将大大增加我们更快推出多种新疫苗的机会。”除了合作协议，诺瓦瓦克斯医药还计划在今年晚些时候启动针对新冠病毒和流感的联合疫苗以及独立流感疫苗的后期试验。此前，公司曾表示试验将仅包括联合疫苗。雅各布斯表示，如果试验成功，公司将不仅拥有一种潜在的可许可疫苗，而且还将开辟自身的有机产品线。","news_type":1},"isVote":1,"tweetType":1,"viewCount":367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}